- Laureate To Add Single-Use Bioreactor (S.U.B.) To Its Portfolio Of Assets
PRINCETON, N.J., Sept. 18 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it is increasing its existing manufacturing capacity by adding two Single-Use Bioreactors (S.U.B.). Acquisition of a 250L and a 1000L S.U.B. will give Laureate greater flexibility in meeting the varying needs of its clients.
The S.U.B. is a single-use alternative to conventional stirred tank bioreactors. The S.U.B. consists of a permanent stainless steel outer support container and a S.U.B. Bioprocess Container (BPC(R)), integrated with an existing bioreactor control system. This makes the S.U.B. a flexible, rapid and economic option to update or increase the bioreactor capacity. The S.U.B. will supplement Laureate's current single-use bioreactors -- Wave Bioreactors(R) and hollow-fiber systems -- as well as the conventional stainless steel stirred-tank bioreactors.
"We are excited about adding the S.U.B. to increase our bioreactor capacity. It is a scalable technology that will support the demand from our growing client base and meet their needs and manufacturing objectives," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate. "The HyClone S.U.B. provides us with all the advantages of single-use bioprocessing, while maintaining aspect ratios and agitation mechanisms comparable to traditional stainless steel stirred-tank bioreactors."
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or firstname.lastname@example.org or visit http://www.laureatepharma.com.
|SOURCE Laureate Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved